Headache and Migraine

A recent study reassured that triptans may be safe for migraine treatment, emphasizing the need for individualized assessments of cardiovascular risks.

Daniel Freedman, PhD, of MIT, gave clinical commentary on how Openwater’s Open-LIFU enables new research into conscious perception and potential clinical applications for conditions like pain and depression.

Teva's fremanezumab gains FDA approval for pediatric migraine prevention, offering a vital treatment option for children aged 6-17.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 1, 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 25, 2025.

The postdoctoral neuropsychology fellow at North Shore University Hospital talked about recognizing and aligning subjective cognitive complaints with objective assessments in patients with migraine during the interictal period. [WATCH TIME: 6 minutes]

The associate professor of neurology at Mayo Clinic Rochester talked about using artificial intelligence-electrocardiogram at baseline to predict adverse vascular events in patients with migraine. [WATCH TIME: 5 minutes]

The associate professor of neurology at Johns Hopkins detailed how artificial intelligence is shaping the future of neurology through its integration in clinical care, research, and medical education. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 18, 2025.

At AHS 2025, the assistant professor of neurology at the Icahn School of Medicine at Mount Sinai highlighted the challenges LGBTQIA+ individuals may face in migraine care. [WATCH TIME: 6 minutes]

Elisabeth Marsh, MD, an associate professor of neurology at Johns Hopkins, shared her insights on the emerging role of AI in clinical practice and neurologic education, ahead of her session at the 2025 ANA/AUPN Annual Meetings.

The assistant professor of neurology at Wake Forest Baptist Atrium Health discussed emerging research on how breast size may contribute to headache disorders, including migraine. [WATCH TIME: 5 minutes]

Nuri Jacoby, MD, neurologist at Maimonides Medical Center and SUNY Downstate, previewed a hands-on session at the upcoming AUP Annual Meeting exploring how simulations can teach communication, professionalism, and feedback skills in neurology training.

The professor of neuroscience at Harvard Medical School highlighted gaps in headache care access, provider training, and medication availability in regions like Kenya and the Philippines. [WATCH TIME: 5 minutes]

The professor and chair of neuroscience at UT Southwestern Medical Center offered an overview on his keynote lecture presented at AHS 2025 on the circadian clock in relation to headache.

Nuri Jacoby, MD, a neurologist at Maimonides Medical Center and SUNY Downstate, previewed his talk at the 2025 AUPN Annual Meeting on using simulation to evaluate nonclinical competencies like communication and professionalism. [WATCH TIME: 3 minutes]

Patients using intranasal zavegepant for acute migraines report significant pain relief and improved daily functioning, highlighting its real-world effectiveness.

The professor of neurology at Albert Einstein College of Medicine talked about new findings presented at AHS, which suggested that both men and women with migraine can face significantly increased risks of ischemic stroke. [WATCH TIME: 5 minutes]

The director of the MedStar Georgetown Headache Center detailed how creative and comparative clinical trials can drive treatment personalization and strengthen clinical confidence. [WATCH: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 11, 2025.

The associate professor of neurology at Mayo Clinic College of Medicine discussed findings presented at AHS 2025 from a post hoc analysis of the phase 3b DELIVER study testing eptinezumab in patients with migraine. [WATCH TIME: 5 minutes]

A recent survey reveals rimegepant's effectiveness for short-term migraine prevention, highlighting user demographics, triggers, and treatment strategies.

Eptinezumab showed significant efficacy in reducing chronic migraine days in Asian patients, potentially addressing a critical unmet need for effective treatments.

The director of the MedStar Georgetown Headache Center explained why data from trials like TEMPLE help strengthen the argument for CGRP therapies as first-line treatments for migraine. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 4, 2025.

Catch up on any of the neurology news headlines you may have missed over the course of June 2025, compiled all into one place by the NeurologyLive® team.

The director of the MedStar Georgetown Headache Center discussed results from the phase 3 TEMPLE trial, which showed improved tolerability and cognitive outcomes with atogepant vs topiramate in episodic migraine. [WATCH TIME: 5 minutes]

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could potentially reshape patient care.

Neurology News Network. for the week ending June 28, 2025. [WATCH TIME: 4 minutes]

A recent survey reveals critical gaps in neurology training on women's health, highlighting the need for urgent curriculum reforms in medical education.